LAUSR

Drug-drug interactions (DDIs) may trigger adverse drug reactions, which endanger the patients. DDI identification before making clinical medications is critical but bears a high cost in clinics. Computational approaches, including global model-based and local model based, are able to screen DDI candidates among a large number of drug pairs by utilizing preliminary characteristics of drugs (e.g. drug chemical structure). However, global model-based approaches are usually slow and don’t consider the topological structure of DDI network, while local model-based approaches have the degree-induced bias that a new drug tends to link to the drug having many DDI. All of them lack an effective ensemble method to combine results from multiple predictors. To address the first two issues, we propose a local classification-based model (LCM), which considers the topology of DDI network and has the relaxation of the degree-induced bias. Furthermore, we design a novel supervised fusion rule based on the Dempster-Shafer theory of evidence (LCM-DS), which aggregates the results from multiple LCMs. To make the final prediction, LCM-DS integrates three aspects from multiple classifiers, including the posterior probabilities output by individual classifiers, the proximity between their instance decision profiles and their reference profiles, as well as the quality of their reference profiles. Last, the substantial comparison with three state-of-the-art approaches demonstrates the effectiveness of our LCM, and the comparison with both individual LCM implementations and classical fusion algorithms exhibits the superiority of our LCM-DS.